Biotech VC deals have best-ever quarter: $2.3bn
This article was originally published in Scrip
Executive Summary
Biotechnology companies had their best quarter on record for venture capital fundraising with 126 companies bringing in $2.3bn during the second quarter as initial public offerings and acquisitions of smaller firms by big pharma continue to fuel VC investment.